Thirty-seven dogs with chronic canine atopic dermatitis (CAD) were treated with pentoxifylline (PTX), 25 mg/kg every 12 hours, given orally with food for at least 4 weeks. Sixteen dogs (43%) were successfully managed: with PTX alone (7 dogs, 19%), PTX with allergen-specific immunotherapy (5 dogs, 13.5%), or PTX with oral glucocorticoids (4 dogs, 10.5%), with follow-up periods of 5 months to 2.5 years.
Introduction
Canine atopic dermatitis (CAD) is a geneticallypredisposed inflammatory and pruritic hypersensitivity (allergic) skin disease with characteristic clinical features 14, 21) . It is usually associated with IgE antibodies to environmental allergens 14, 22) . Although the true prevalence of CAD is unknown, it is estimated to be around 10% of the canine population 14, 22) . The treatment of CAD is multifaceted and consists of a combination of actions that include the use of allergen avoidance, antiinflammatory drugs, allergen-specific immunotherapy, and antimicrobial drugs 14, 22) .
The etiopathogenesis of CAD is complex 14, 22) . Increased phosphodiesterase (PDE) activity has been reported in dogs and humans 2, 11) . Increased PDE activity seems to be responsible for the deficient cyclic adenosine monophosphate (cAMP) response in atopic dogs and humans 1, 4, 11) . Pentoxifylline (PTX) is a methylxanthine derivative and a nonselective PDE inhibitor 3, 7, 11, 20, 22) . PDE inhibition produces increased intracellular concentrations of cAMP, which has numerous cell-stabilizing and antiinflammatory effects (Table 1) 3, 5-7, 11, 13, 15, 20, 22, 24) .
PTX is rapidly absorbed when given orally, with a bioavailability of about 20 to 30% 8, 18) . Absorption and bioavailability are not affected when the drug is given with food 8, 18, 19) . First-pass metabolism in the liver results in the formation of several metabolites, the major ones being M1 and M5 8, 18) . Ninety percent of PTX and its metabolites are excreted in the urine. In humans, plasma PTX concentrations are increased with concurrent administration of cimetidine, and PTX increases the risk of bleeding when administered with aspirin, and the risk of hypoglycemia when administered with insulin 3, 20) . In humans, PTX is not used in nursing mothers, and is contraindicated with significant renal or hepatic disease, and with bleeding disorders 3, 20) . Fetal abnormalities were produced when PTX was administered to pregnant rodents 20) .
PTX has been used in veterinary dermatology to treat a great number of skin disorders 7, 10, 16, 17, 22, 23) . Virtually all such information is anecdotal. Early treatment protocols with PTX in dogs were also anecdotal and highly variable: from 400 mg/dog every 8 to 48 hours, to 10 mg/kg every 8 to 24 hours 7, 16, 22) . In 2000, the authors of a study on the pharmacokinetics of PTX in 7 healthy mongrel dogs recommended a therapeutic protocol of 15 mg/kg every 8 hours 8) . The authors of another study on the pharmacokinetics of PTX in 8 healthy mongrel dogs suggested a therapeutic protocol of 25 to 30 mg/kg every 12 hours 18) . PTX (10 mg/kg every 12 hours) was administered for 4 weeks to 10 dogs with CAD in a double-blinded, placebo-controlled study 9) . Overall, erythema and pruritus scores achieved median reductions of 0% and 30%, respectively. Thirty percent and 40% of the dogs achieved at least a 50% reduction in erythema and pruritus scores, respectively. No dog was reported to be satisfactorily controlled.
In a 2003 study, PTX was administered to 10 dogs with familial dermatomyositis 19) . The authors concluded that a protocol of 25 mg/kg every 12 hours produced the best control of skin lesions. In humans, the clinical effect of PTX is known to be dose-related 3, 8, 20) . This also appears to be the case in dogs 10, 11, 17, 23) . The purpose of our study was to evaluate the efficacy of a higher dose of PTX for the control of pruritus in CAD.
Materials and Methods
Thirty-seven dogs examined at the Cornell University Companion Hospital from 2002 to 2005 were randomly selected to participate in this study. All dogs had classical historical and clinical features of CAD 14, 22) , but were otherwise healthy. No dog fulfilled the provisional diagnostic criteria for psychogenic dermatoses featuring pruritic behavior 12) . Various purebred dogs and mongrels were represented, including 20 females and 17 males ( Table 2) . Their ages ranged from 2 to 12 years, and they weighed between 2.5 and 50 kg. The duration of clinical signs related to CAD ranged from 1 to 10.5 years. All dogs had non-seasonal pruritus. All dogs had multiple positive reactions-which correlated well with their allergen exposure and history-with intradermal testing, allergen-specific IgE serology, or both of these. All dogs failed to respond to a home-cooked novel protein diet fed for 4 to 6 weeks. Thirty-three dogs had received appropriate anti-inflammatory doses of glucocorticoids (prednisone, methylprednisolone, dexamethasone) by mouth 22) , and their pruritus completely resolved ( Table   Table 1 3). Thirty-one dogs had previously received one or more n o n s t e r o i d a l a n t i -i n f l a m m a t o r y a g e n t s o r immunomodulating procedures with no reduction of the pruritus (Table 3) . Notably, 8 dogs had failed to respond to 1 to 1 1 /2 years of allergen-specific immunotherapy, and 5 dogs had failed to respond to cyclosporine. Any dog with concurrent bacterial pyoderma, Malassezia dermatitis, or ectoparasite infestation was treated appropriately prior to beginning the PTX trial. All dogs included in the trial had moderate to severe, multifocal to generalized pruritus. Twenty-nine of the dogs received only PTX during the trial. Five dogs (cases 10, 16, 17, 24, 25) received concurrent allergen-specific immunotherapy, which had been given for 1 to 1 1 /2 years with a 50% reduction in pruritus. Four dogs (cases 30, 32, 34, 35) received concurrent oral glucocorticoids, which they had been receiving for several weeks. After 4 weeks of PTX treatment, the owners of the dogs receiving concurrent glucocorticoids began to reduce the dose or frequency of administration of the glucocorticoids to evaluate any possible steroid-sparing effect of the PTX. The dogs were treated with PTX (Pentoxifylline Extended-Release Tablets, 400 mg tablets; Apotex Inc., Toronto, Ontario, Canada) by mouth, with food, 25 mg/ kg every 12 hours for 4 weeks. Neither the owners nor the clinicians were blinded to the treatment. The owners evaluated response to treatment. The owners were asked to monitor and record any reduction of the dogs' pruritus (scratching, licking, chewing, rubbing). Therapy was deemed successful only if the patient's pruritus was reduced to a tolerable level: both the owner and the dog being comfortable. If a reduction in pruritus or in glucocorticoid requirement was seen in dogs receiving concurrent allergen-specific immunotherapy or glucocorticoids, respectively, PTX therapy was stopped and restarted to document any beneficial effect.
Results
Sixteen of the 37 dogs (43%) had a good response to PTX. In 7 dogs (19%) (cases 3, 6, 7, 8, 18, 29, 36) there was a good response to PTX alone, which was maintained for follow-up periods of 5 months to 2.5 years.
Five dogs (13.5%) (cases 10, 16, 17, 24, 25) that had been receiving allergen-specific immunotherapy with a 50% reduction in their pruritus, achieved complete control of their pruritus while receiving PTX for follow-up periods of 1 to 2.5 years. When PTX was discontinued, pruritus increased to its former levels in all 5 dogs. Reinstituting PTX in these dogs again resulted in complete control of pruritus.
Four dogs (10.5%) (cases 30, 32, 34, 35) that had been receiving oral glucocorticoids achieved reductions in their dose requirement: 10-fold reduction (case 30), 0.33-fold reduction (case 32), 3-fold reduction (case 34), and 2.5fold reduction (case 35). These dose reductions were maintained for follow-up periods of 5 months to 1.5 years.
Only 2 dogs experienced possible side effects. One dog (case 37) refused to take PTX. Another dog (case 11) developed diarrhea a few days after beginning PTX, which resolved when PTX was discontinued. As PTX was not readministered to this dog, a true cause-and-effect relationship between PTX and the diarrhea could not be established.
Discussion
PTX is a useful antipruritic agent for CAD when used at a higher dose-25 mg/kg every 12 hours-than previously recommended 9) . This is consistent with several anecdotal reports 10, 11, 17, 23) . In our study, 43% of the dogs with CAD were successfully managed with PTX alone, or in combination with allergen-specific immunotherapy or oral glucocorticoids. It is noteworthy that 27 of 37 dogs (73%) in our study had very chronic CAD, with a duration of disease of 3 or more years. In addition, the dogs in our study had failed to respond to a variety of therapeutic interventions: one or more antihistamines (80% of dogs), omega-6/omega-3 fatty acid supplements (38%), allergen-specific immunotherapy (22%), and cyclosporine (13%).
Anecdotal reports suggest that PTX (1) does not work as well for generalized pruritus, (2) is not beneficial as a stand-alone drug for pruritus, (3) is more effective in older (>8 years) dogs, and (4) is more effective for grass allergies than for house dust mite allergies 10, 17) . The results of our study do not corroborate these anecdotes. All of the dogs that responded to PTX in our study had multifocal or generalized pruritus. PTX was effective as a standalone drug in 19% of our dogs. Fifty percent of the dogs that responded to PTX were 1.5 to 4 years old. Twelve of the 16 dogs (75%) in our study that responded to PTX had positive reactions to one or both house dust mites (Dermatophagoides farinae, D. pteronyssinus).
PTX has been reported to have steroid-sparing effects in dogs and humans 3, 7, 9, 20) . This was also observed in our study. A 0.33-to 10-fold reduction in glucocorticoid requirement was achieved with concurrent PTX in 4 (10.5%) of our dogs.
PTX is also a useful adjunctive therapeutic agent in dogs receiving allergen-specific immunotherapy. Five (13.5%) of the dogs in our study had been receiving allergen-specific immunotherapy for 1 to 1.5 years with a 50% reduction in pruritus. When PTX was added to the treatment plan the pruritus in all 5 dogs was completely controlled.
Side effects are reported to rarely occur with PTX in dogs, even at the higher dose 7, 8-11, 16-19, 22, 23) . Nausea, vomiting, and diarrhea are most commonly mentioned. Our findings are in agreement with these observations. One dog in our study refused to take the PTX and another dog developed diarrhea (no cause-and-effect relationship documented). Other possible side effects associated with PTX administration in dogs, according to anecdotal literature, include excitement, nervousness, flushing, thrombocytopenia, bone marrow suppression, increased prothrombin time, and erythema multiforme 7, 10, 16, 17, 23) .
Anecdotal literature also indicates that generic forms of PTX are more commonly associated with therapeutic failure and side effects 16, 17) . Our study did not address these anecdotal reports as all of our dogs were treated with a generic form of PTX. A future study comparing the benefits of generic and proprietary PTX will be needed to resolve these issues.
In conclusion, we found PTX to be a useful agent for the control of pruritus in dogs with CAD. It was effective as a stand-alone drug, as a steroid-sparing drug, and in combination with allergen-specific immunotherapy. Side effects were rare and mild.
